Literature DB >> 32030286

Neoadjuvant radiation therapy for esophageal cancer: is a higher dose better?

Waqar Haque1, E Brian Butler1, Bin S Teh1.   

Abstract

Entities:  

Year:  2019        PMID： 32030286      PMCID： PMC6988049          DOI： 10.21037/jtd.2019.11.77

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.

Authors:  S G Urba; M B Orringer; A Turrisi; M Iannettoni; A Forastiere; M Strawderman
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

2.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

3.  Salvage esophagectomy for persistent or recurrent disease after definitive chemoradiation.

Authors:  Stephen G Swisher; Jenifer Marks; David Rice
Journal:  Ann Cardiothorac Surg       Date:  2017-03

4.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

5.  Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.

Authors:  Bryan H Burmeister; B Mark Smithers; Val Gebski; Lara Fitzgerald; R John Simes; Peter Devitt; Stephen Ackland; David C Gotley; David Joseph; Jeremy Millar; John North; Euan T Walpole; James W Denham
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

6.  Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.

Authors:  B D Minsky; D Neuberg; D P Kelsen; T M Pisansky; R J Ginsberg; T Pajak; M Salter; A B Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

7.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

Authors:  Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

8.  Induction Radiation Therapy for Esophageal Cancer: Does Dose Affect Outcomes?

Authors:  Tara R Semenkovich; Pamela P Samson; Jessica L Hudson; Melanie Subramanian; Bryan F Meyers; Benjamin D Kozower; Daniel Kreisel; G Alexander Patterson; Clifford G Robinson; Jeffrey D Bradley; Varun Puri
Journal:  Ann Thorac Surg       Date:  2018-11-13       Impact factor: 4.330

9.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.